JMJD2D (human, recombinant)

Methylation of lysine residues in core histones plays a critical role in regulating gene expression. Jumonji domain containing 2D (JMJD2D) catalyzes the demethylation of di- and tri-methylated forms of histone H3 at lysine residue 9 (me 2/3), leading to transcriptional repression and activation, respectively. Like other JmjC protein hydroxylase family members, JMJD2D is an alpha-ketoglutarate-dependent Fe (II) oxygenase. Because of their implication in cancer cell growth, jumonji C domain-containing histone demethylase inhibitors may have the capacity to be anticancer agents.Synonyms: JHDM3D, Jumonji Domain Containing 2D, KDM4D, Lysine-Specific Demethylase 4D. Purity: >75% estimated by SDS-PAGE. Source: Active human recombinant N-terminal His-tagged protein, expressed in E. coli. MW: 42.7 kDa. Formulation: (Request formulation change), A solution in 50 mM HEPES, pH 7.4, with 150 mM sodium chloride and 20% glycerol. UniProt Accession #: Q6B0I6.